Study of Sugammadex dose required for antagonism of postoperative neuromuscular blockade.

Study of Sugammadex dose required for antagonism of postoperative neuromuscular blockade. - Study of Sugammadex dose required for antagonism of postoperative neuromuscular blockade.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055235

Enrollment

Registered

2024-08-20

Start date

2023-10-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery under general anesthesia with neuromuscular blockade

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases in which surgery is performed under general anesthesia and ICU management is continued under sedation and intubation without awakening the patient after surgery.

Exclusion criteria

Exclusion criteria: Sugammadex allergy Hepatic failure Receiving aminoglycoside antibiotics

Design outcomes

Primary

Measure	Time frame
Sugammadex dose required for T1 recovery in muscle relaxation monitoring	—

Secondary

Measure	Time frame
Sugammadex dose required to recover TOF ratio Dose of sugammadex that does not cause re-muscle relaxation	—

Countries

Japan

Contacts

Public ContactTomoya Taniguchi

Nagoya University Hospital Department of Anesthesiology

taniguchi.tomoya.f6@f.mail.nagoya-u.ac.jp052-741-2340

Outcome results